13.99 +0.14 (1.01%)
After hours: 7:58PM EDT
|Bid||13.81 x 3100|
|Ask||14.05 x 3000|
|Day's range||13.12 - 15.89|
|52-week range||12.52 - 22.40|
|Beta (5Y monthly)||1.37|
|PE ratio (TTM)||N/A|
|Earnings date||03 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||33.56|
Shares of Heron Therapeutics (NASDAQ: HRTX) were jumping 7.3% as of 3:08 p.m. EDT on Monday after rising as much as 13% earlier in the day. Heron announced Q1 revenue of $20 million, down 21% year over year. The average analysts' estimate projected Q1 revenue of $25.7 million and a loss of $0.57 per share.
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -1.75% and -25.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.